The status of hemoglobin-based red cell substitutes

Area of Science:

• Biomedical Engineering
• Hematology
• Pharmacology

Background:

• The demand for blood transfusions is increasing due to factors like donor blood shortages, transfusion risks, and logistical challenges.
• Developing artificial oxygen carriers aims to address these limitations and provide alternatives to traditional blood transfusions.
• Significant progress has been made in understanding hemoglobin interactions, leading to improved red cell substitute candidates.

Purpose of the Study:

• To review the current status of red cell substitutes.
• To provide an update on pre-clinical and clinical experiences with these artificial oxygen carriers.
• To assess the safety and efficacy of developing red cell substitutes.

Main Methods:

• Review of pre-clinical data on red cell substitutes.
• Analysis of clinical trial results for oxygen-carrying fluids.
• Evaluation of safety and efficacy profiles of investigational products.

Main Results:

• Seven red cell substitute products are undergoing clinical testing for applications including trauma, surgery, sepsis, cancer, and anemia.
• While some trials faced challenges, most products demonstrate minimal to no toxicity.
• Early clinical trials show encouraging results, supporting continued development of oxygen-carrying fluids.

Conclusions:

• Red cell substitutes represent a promising advancement in transfusion medicine.
• Further development is warranted based on positive early clinical outcomes and manageable safety profiles.
• Artificial oxygen carriers may soon become a viable clinical option, alleviating pressures on blood banking systems.